What’s New
Explore latest events, medical insights and trends.
To Be a Detective: Finding Gaucher Patients
Hint 1: All-In-One Tool for Easier Gaucher Patient Identification
Dupilumab Real-World Effectiveness in CRSwNP: AROMA Registry Results
Explore global real-world data from the AROMA registry on dupilumab effectiveness in CRSwNP patients, both surgery-naïve and post-surgery.
Real-Life Indirect Case Matched Comparison of Dupilumab and Tezepelumab on Airway Oscillometry
Nirsevimab in Focus: Clinical Insights into RSV Protection
Join Professor Yung Chee Fu as he presents the compelling clinical evidence behind nirsevimab (Beyfortus), a breakthrough single-dose solution for RSV protection in all infants. Through comprehensive trial data, Prof. Yung demonstrates nirsevimab's remarkable 70-86% efficacy in preventing RSV-related hospitalizations across all infant populations. The presentation highlights how Nirsevimab provides extended protection beyond five months, making it particularly valuable for Singapore's year-round RSV season, while maintaining an excellent safety profile across all gestational ages.
Patient-Video
Request-form
